Discover what's new.

Access the latest news, business developments, company updates, industry trends, events and more.

| By Kelley Gipson

IsoPlexis pulls in additional $20M funding

IsoPlexis has raised an additional $20 million in its Series C financing, bringing the entire Series C round to $45 million. The funding will continue to...

| By Kelley Gipson

ReNetX gets Fast Track for spinal cord treatment

ReNetX Bio reports that the FDA has granted the company Fast Track Designation for ReNetX Bio’s clinical therapy (AXER-204) for the potential treatment of Chronic Spinal...

| By Kelley Gipson

Thetis 2019 recap and 2020 outlook

Gary Mathias, Co-Founder and CEO of Thetis Pharmaceuticals, recently shared the following message. Happy New Year from the Thetis team! I am glad to report...

| By Kelley Gipson

ABCT announces 2020 life sciences cohort

ABCT, the Accelerator for Biosciences in Connecticut, has announced the second cohort of emerging biosciences ventures invited to participate in its annual program. The 2020 ABCT cohort...

| By Kelley Gipson

CTNext mentor network applications due 1/15

CTNext is looking for startup companies that are poised for growth, but need access to some specialized, quality expertise to accelerate to the next level....

| By Kelley Gipson

Cancer therapy leads to insights into lupus

In the last decade, scientists discovered that blocking a key regulator of the immune system helped unleash the body’s natural defenses against several forms of...

| By Kelley Gipson

JAX team to study cancer immunotherapy

The Jackson Laboratory (JAX) has received $2.5 million from The Mark Foundation for Cancer Research to study in mice the influence of host genetics on...

| By Kelley Gipson

BioXcel announces Phase 3 agitation studies

BioXcel Therapeutics has announced announced the initiation of its SERENITY (Sub-Lingual DExmedetomidine in Agitation Associated With SchizophRENIa and Bipolar Disorder STudY) program, two Phase 3 studies of...

| By Kelley Gipson

Melinta announces restructuring agreement

Melinta Therapeutics has entered into a restructuring support agreement with the lenders pursuant to a pre-negotiated chapter 11 plan of reorganization. “We are confident that...